Christopher J. Senner - 02 Jan 2025 Form 4 Insider Report for Quince Therapeutics, Inc. (QNCX)

Role
Director
Signature
/s/ Brendan Hannah, Attorney-in-Fact
Issuer symbol
QNCX
Transactions as of
02 Jan 2025
Net transactions value
$0
Form type
4
Filing time
08 Jan 2025, 19:29:14 UTC
Previous filing
19 Nov 2024
Next filing
17 Jan 2025
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction QNCX Director Stock Option (right to buy) Award $0 +35,274 $0.000000 35,274 02 Jan 2025 Common Stock 35,274 $1.88 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares subject to the option shall vest in equal quarterly installments over a one year-period. The Reporting Person elected to receive the stock options in lieu of the annual director cash retainer for 2025 provided for under the Issuer's Outside Director Compensation Policy.